Thursday, April 21, 2022

Lysogene Publishes Positive Preliminary Preclinical Results in the Treatment of Fragile X Syndrome

Lysogene (FR0013233475 – LYS), a phase 3 gene therapy platform Company targeting central nervous system (CNS) diseases, announced today the ...
https://www.google.com/url?rct=j&sa=t&url=https://thefacts.com/ap/business/article_1f1710b3-454a-5998-a884-f651c445b3e6.html&ct=ga&cd=CAIyGmEyNDJjNTAxZWU3OTQyNzI6Y29tOmVuOlVT&usg=AOvVaw1-LAMq6twn5aRvEwM43AtZ
-

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)

2 muggers captured by RU students on campus - UNB

Rayhanul Ferdous, a student of Genetic Engineering and Biotechnology department who had his phone stolen told UNB: “I was walking on the eas...